Frontiers in Pediatrics (Sep 2020)

Use of Adjunctive Therapy in Acute Kawasaki Disease in Latin America

  • Brenda Fortuna-Reyna,
  • Emelia V. Bainto,
  • Emelia V. Bainto,
  • Rolando Ulloa-Gutierrez,
  • Rolando Ulloa-Gutierrez,
  • Luis M. Garrido-García,
  • Dora Estripeaut,
  • Olguita del Águila,
  • Virgen Gómez,
  • Enrique Faugier-Fuentes,
  • Greta Miño-León,
  • Sandra Beltrán,
  • Fernanda Cofré,
  • Enrique Chacón-Cruz,
  • Patricia Saltigeral-Simental,
  • Lucila Martínez-Medina,
  • Lourdes Dueñas,
  • Kathia Luciani,
  • Francisco J. Rodríguez-Quiroz,
  • German Camacho-Moreno,
  • Tamara Viviani,
  • Martha I. Alvarez-Olmos,
  • Heloisa Helena de Sousa Marques,
  • Eduardo López-Medina,
  • María C. Pirez,
  • Adriana H. Tremoulet,
  • Adriana H. Tremoulet

DOI
https://doi.org/10.3389/fped.2020.00442
Journal volume & issue
Vol. 8

Abstract

Read online

Objective: To characterize the use of adjunctive therapy in Kawasaki disease (KD) in Latin America.Methods: The study included 1,418 patients from the Latin American KD Network (REKAMLATINA) treated for KD between January 1, 2009, and May 31, 2017.Results: Of these patients, 1,152 received only a single dose of IVIG, and 266 received additional treatment. Age at onset was similar in both groups (median 2 vs. 2.2 years, respectively). The majority of patients were male (58 vs. 63.9%) and were hospitalized with the first 10 days of fever (85.1 vs. 84.2%). The most common adjunctive therapy administered was steroids for IVIG-resistance, followed by additional doses of IVIG. The use of biologics such as infliximab was limited. KD patients who received adjunctive therapy were more likely to have a lower platelet count and albumin level as well as a higher Z score of the coronary arteries.Conclusion: This is the first report of adjunctive therapies for KD across Latin America. IVIG continues to be the initial and resistance treatment, however, steroids are also used and to a lesser extent, biological therapy such as infliximab. Future studies should address the barriers to therapy in children with acute KD throughout Latin America.

Keywords